Log in to post a reply
Aug 3, 2018 11:20PM
Aug 3, 2018 11:37PM
Clinical trial results of tucatinib with T-DM1 shows promise in treating HER2+ breast cancer
Phase 1b clinical trial results published in JAMA Oncology show promise for the combination of tucatinib (formerly ONT-380) with T-DM1 against heavily pretreated HER2-positive breast cancer. Of 57 patients treated, 48 percent responded to the combination, with cancer control of median 8.2 months. Importantly, tucatinib acted against brain metastases stemming from HER2+ breast cancer, a major cause of mortality from the disease.
"One of the best things about this drug is that it combines well with nearly everything. It is so well tolerated that when you test tucatinib in combination with other drugs, it feels like you're just giving the other drug. It's a pill. It works. And it hardly causes side effects. It's really a doctor's dream," says Virginia Borges, MD, MMSc, director of the Breast Cancer Research Program and Young Women's Breast Cancer Translational Program at CU Cancer Center.
.... tucatinib is being evaluated in a number of other trials and with additional partners...
Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer
- In this phase IB study of 57 patients with metastatic or unresectable locally advanced ERBB2/HER2-positive breast cancer treated previously with trastuzumab and a taxane, the maximum tolerated dosage of tucatinib combined with ado-trastuzumab emtansine was determined to be 300 mg administered orally twice daily; the objective response rate was 48%. Median progression-free survival was 8.2 months.
- Tucatinib in combination with ado-trastuzumab emtansine had acceptable toxicity and showed preliminary antitumor activity among heavily pretreated patients with ERBB2/HER2-positive metastatic breast cancer with and without brain metastases.
"If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride."
2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC)
1/14/2016 Herceptin (trastuzumab)
1/14/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel)
2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+